Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Omnicell Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Omnicell kazanç ve gelirin sırasıyla yıllık 116.1% ve 4.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 116.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7% olacağı tahmin edilmektedir.

Anahtar bilgiler

116.1%

Kazanç büyüme oranı

116.8%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.5%
Gelir büyüme oranı	4.6%
Gelecekteki özkaynak getirisi	7.0%
Analist kapsamı	Good
Son güncelleme	01 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Oct 07

Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%

Aug 02

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Mar 28

Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 29

Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Feb 23

Omnicell Is Building A Strong Moat

Feb 22

Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Jan 15

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Dec 25

Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Dec 06

Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Nov 10

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Sep 06

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

Aug 08

Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

Jul 02

A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Jun 08

Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Apr 29

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Apr 11

At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Mar 23

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Feb 28

Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

Jan 15

We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Jan 01

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Nov 17

Analysts Just Slashed Their Omnicell, Inc. (NASDAQ:OMCL) EPS Numbers

Nov 03

Omnicell launches Specialty Pharmacy Services

Oct 11

Omnicell (NASDAQ:OMCL) Seems To Use Debt Quite Sensibly

Sep 30

Omnicell says advance services to drive profitable growth in long-run: Investor Day

Sep 20

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Sep 15

Omnicell (NASDAQ:OMCL) Might Have The Makings Of A Multi-Bagger

Aug 31

Omnicell reports Q2 earnings miss; reaffirms FY22 guidance and issues Q3 outlook

Aug 04

Are Investors Undervaluing Omnicell, Inc. (NASDAQ:OMCL) By 41%?

Aug 03

Omnicell Fails To Justify Inclusion In Long-Only, Equity-Focused Portfolio

Jul 21

We Ran A Stock Scan For Earnings Growth And Omnicell (NASDAQ:OMCL) Passed With Ease

Jun 27

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Jun 13

Omnicell's (NASDAQ:OMCL) Returns On Capital Are Heading Higher

May 30

These 4 Measures Indicate That Omnicell (NASDAQ:OMCL) Is Using Debt Safely

May 05

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:OMCL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,202	30	61	122	4
12/31/2025	1,144	19	35	111	8
12/31/2024	1,091	2	29	117	8
6/30/2024	1,080	-21	152	204	N/A
3/31/2024	1,103	-21	165	218	N/A
12/31/2023	1,147	-20	126	181	N/A
9/30/2023	1,186	-34	165	225	N/A
6/30/2023	1,235	-23	127	189	N/A
3/31/2023	1,268	-18	48	107	N/A
12/31/2022	1,296	6	17	78	N/A
9/30/2022	1,309	48	-5	55	N/A
6/30/2022	1,258	61	18	77	N/A
3/31/2022	1,199	72	98	158	N/A
12/31/2021	1,132	78	173	232	N/A
9/30/2021	1,070	80	195	249	N/A
6/30/2021	987	60	194	242	N/A
3/31/2021	914	35	164	218	N/A
12/31/2020	892	32	131	186	N/A
9/30/2020	891	38	86	144	N/A
6/30/2020	906	49	101	164	N/A
3/31/2020	924	69	85	144	N/A
12/31/2019	897	61	83	145	N/A
9/30/2019	860	54	98	158	N/A
6/30/2019	836	48	59	117	N/A
3/31/2019	807	38	55	112	N/A
12/31/2018	787	38	50	104	N/A
9/30/2018	772	54	8	61	N/A
6/30/2018	754	48	-19	27	N/A
3/31/2018	747	44	N/A	16	N/A
12/31/2017	713	31	N/A	25	N/A
9/30/2017	688	-1	N/A	45	N/A
6/30/2017	678	-6	N/A	72	N/A
3/31/2017	670	-9	N/A	56	N/A
12/31/2016	696	10	N/A	50	N/A
9/30/2016	651	8	N/A	54	N/A
6/30/2016	599	14	N/A	40	N/A
3/31/2016	539	24	N/A	44	N/A
12/31/2015	485	31	N/A	38	N/A
9/30/2015	476	32	N/A	37	N/A
6/30/2015	463	32	N/A	50	N/A
3/31/2015	455	31	N/A	75	N/A
12/31/2014	441	31	N/A	65	N/A
9/30/2014	425	28	N/A	49	N/A
6/30/2014	407	29	N/A	59	N/A
3/31/2014	395	27	N/A	52	N/A
12/31/2013	381	24	N/A	55	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OMCL önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: OMCL önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: OMCL önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: OMCL şirketinin gelirinin (yıllık 4.6% ) US pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OMCL şirketinin gelirinin (yıllık 4.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OMCL 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7 %).

Omnicell Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 17% to US$38.29

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Consensus EPS estimates fall by 732%

Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Fiscal Year 2024

Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Price target decreased by 28% to US$44.50

Recent updates

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Omnicell, Inc. Announces Central Med Automation Service

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 17% to US$38.29

Omnicell, Inc.'s (NASDAQ:OMCL) Price Is Right But Growth Is Lacking After Shares Rocket 49%

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Omnicell, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Is There Now An Opportunity In Omnicell, Inc. (NASDAQ:OMCL)?

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Now 20% undervalued

Omnicell (NASDAQ:OMCL) Is Making Moderate Use Of Debt

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Omnicell, Inc. Announces XT Amplify

Omnicell, Inc. to Report Q1, 2024 Results on May 02, 2024

Omnicell, Inc., Annual General Meeting, May 21, 2024

An Intrinsic Calculation For Omnicell, Inc. (NASDAQ:OMCL) Suggests It's 29% Undervalued

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

New minor risk - Shareholder dilution

High number of new directors

Omnicell, Inc. Announces Executive Changes

Omnicell, Inc.'s (NASDAQ:OMCL) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is It Too Late To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell Is Building A Strong Moat

Consensus EPS estimates fall by 732%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Omnicell, Inc. Reports Unaudited Impairment Changes Results for the Fourth Quarter Ended December 31, 2023

Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Fiscal Year 2024

Omnicell, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Does Omnicell (NASDAQ:OMCL) Have A Healthy Balance Sheet?

Omnicell, Inc. Announces Board Changes

Benign Growth For Omnicell, Inc. (NASDAQ:OMCL) Underpins Its Share Price

Is Omnicell, Inc. (NASDAQ:OMCL) Trading At A 48% Discount?

Omnicell, Inc. (NASDAQ:OMCL) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Price target decreased by 28% to US$44.50

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 7.7% to US$64.14

Omnicell, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 27% Undervaluation?

Omnicell, Inc. Announces Board Changes

Now 20% undervalued after recent price drop

Would Omnicell (NASDAQ:OMCL) Be Better Off With Less Debt?

New minor risk - Shareholder dilution

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Omnicell, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Omnicell, Inc. Appoints Bobby Ghoshal to Board of Directors

Why Omnicell, Inc. (NASDAQ:OMCL) Could Be Worth Watching

Founder recently bought US$295k worth of stock

A Look At The Fair Value Of Omnicell, Inc. (NASDAQ:OMCL)

Omnicell Announces Leadership and Organizational Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investors Could Be Concerned With Omnicell's (NASDAQ:OMCL) Returns On Capital

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

At US$55.77, Is Omnicell, Inc. (NASDAQ:OMCL) Worth Looking At Closely?

Lead Independent Director exercised options and sold US$377k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 42% Undervaluation?

Consensus EPS estimates fall by 19%

Omnicell, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Returns On Capital Are Showing Encouraging Signs At Omnicell (NASDAQ:OMCL)

We Think Omnicell (NASDAQ:OMCL) Can Stay On Top Of Its Debt

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Consensus forecasts updated

Consensus forecasts updated

Omnicell, Inc. to Showcase Advanced Services Designed to Deliver Enhanced Medication Management Outcomes at ASHP Midyear 2022

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Is There An Opportunity With Omnicell, Inc.'s (NASDAQ:OMCL) 46% Undervaluation?

Price target decreased to US$84.44